Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder (Q37914849)

25 August 2017

1 reference

title

Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder (English)

1 reference

25 August 2017

Michael G Oefelein

1

1 reference

25 August 2017

publication date

1 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

34

1 reference

25 August 2017

issue

9

1 reference

25 August 2017

page(s)

733-754

1 reference

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Muscarinic receptor antagonists for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Transdermal drug delivery treatment for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

The Q-T interval and antimuscarinic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Solifenacin succinate for the treatment of symptoms of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Muscarinic receptors in the bladder: from basic research to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Tolterodine: a review of its use in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Drug interactions that matter. A critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Tolterodine-warfarin drug interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Evaluation of drug-drug interactions with fesoterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Clinical pharmacokinetics of trospium chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Trospium chloride is undetectable in the older human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

The clinical pharmacokinetics of darifenacin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Assessment of cognitive function of the elderly population: effects of darifenacin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Trospium and cognition in patients with late onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Effect of tolterodine on sleep structure modulated by CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Oxybutynin and cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Cognitive dysfunction with tolterodine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Transient memory impairment and hallucinations associated with tolterodine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

hERG potassium channels and cardiac arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Comparison of fesoterodine and tolterodine in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Fesoterodine dose response in subjects with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

An investigation of dose titration with darifenacin, an M3-selective receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Epidemiology of constipation in North America: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

The problems of anticholinergic adverse effects in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Persistence of antimuscarinic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592790-000000000-00000

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

21 January 2018

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin

1 reference

12 December 2020

Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence

1 reference

12 December 2020

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

1 reference

12 December 2020

Anticholinergic drug use and bowel function in nursing home patients

1 reference

12 December 2020

Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial

1 reference

12 December 2020

Which anticholinergic drug for overactive bladder symptoms in adults

1 reference

12 December 2020

The implications of poor medication persistence with treatment for overactive bladder

1 reference

12 December 2020

Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia

1 reference

12 December 2020

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

12 December 2020

Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies

1 reference

12 December 2020

Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial

1 reference

12 December 2020

Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study

1 reference

12 December 2020

Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin

1 reference

12 December 2020

Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential

1 reference

12 December 2020

Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg

1 reference

12 December 2020

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

1 reference

12 December 2020

Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin

1 reference

12 December 2020

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

1 reference

12 December 2020

Definition and epidemiology of overactive bladder

1 reference

12 December 2020

Management of the overactive bladder: a review of pharmacological therapies and methods used by the urological specialist.

1 reference

12 December 2020

Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications

1 reference

12 December 2020

Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial

1 reference

12 December 2020

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder

1 reference

12 December 2020

Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence

1 reference

12 December 2020

Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers

1 reference

12 December 2020

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

1 reference

12 December 2020

Overactive bladder: recognition requires vigilance for symptoms.

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

12 December 2020

Anticholinergics and central nervous system effects: are we confused?

1 reference

12 December 2020

Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan

1 reference

12 December 2020

Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder

1 reference

12 December 2020

Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

12 December 2020

Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia

1 reference

12 December 2020

[Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test]

1 reference

12 December 2020

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

1 reference

12 December 2020

Safety and tolerance of trospium chloride in the high dose range

1 reference

12 December 2020

Polypharmacy: when is it rational?

1 reference

12 December 2020

Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability

1 reference

12 December 2020

Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial

1 reference

12 December 2020

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

1 reference

12 December 2020

Probable interaction between tolterodine and warfarin

1 reference

12 December 2020

Anticholinergic effects of medication in elderly patients.

1 reference

12 December 2020

Thorough QT study with recommended and supratherapeutic doses of tolterodine

1 reference

12 December 2020

Persistence with overactive bladder pharmacotherapy in a Medicaid population.

1 reference

12 December 2020

Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity

1 reference

12 December 2020

Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study

1 reference

12 December 2020

Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials

1 reference

12 December 2020

Concomitant medications and possible side effects of antimuscarinic agents

1 reference

12 December 2020

10.2165/11592790-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1012338417

0 references

1 reference